FDA Brief

Warning letters Food

FDA warning letter to

Curtis Jacquot dba Pacific BioLogic Co.

High riskIssued Dec 21, 2023Posted Feb 13, 2024Division of Human and Animal Food Operations West V

Pacific BioLogic's dietary supplements had manufacturing violations and disease claims making them unapproved drugs.

What happened

FDA inspected the Concord, CA facility June 1 through 29, 2023 and found significant violations of current good manufacturing practice (CGMP) for dietary supplements, including missing specifications, master manufacturing records, batch production records, complaint records, reserve samples, and quality control checks. FDA also reviewed labels and websites in July 2023 and found disease claims making several supplements unapproved new drugs, plus labeling violations; it said the company’s July 14, 2023 response was inadequate.

What FDA found

  1. Website claims that products treat diseases made several supplements unapproved new drugs and drugs with inadequate directions.

    FD&C Act §§ 201(g)(1)(B), 201(p), 301(d), 502(f)(1), 505(a) [21 U.S.C. §§ 321(g)(1)(B), 321(p), 331(d), 352(f)(1), 355(a)]
  2. The company did not establish required specifications for components, labels and packaging, and finished dietary supplements.

    21 CFR 111.70(b), (d), (e)
  3. The company did not prepare written master manufacturing records for some products and its records for others lacked required content.

    21 CFR 111.205(a), 111.210
  4. The company did not prepare a batch production record for any finished product.

    21 CFR 111.255(a)
  5. The company failed to review and record complaints, document returned-product disposition, keep reserve samples, and ensure quality control matched components to labels.

    21 CFR 111.560(a)(1), 111.570(b)(2), 111.535(b)(2), 111.83(a), 111.105
  6. Labels failed to declare common or usual ingredient names and plant parts as required.

    FD&C Act §§ 403(i)(2), 403(s)(2)(C) [21 U.S.C. §§ 343(i)(2), 343(s)(2)(C)]; 21 CFR 101.36, 101.4(h)

What FDA wants

FDA tells the company to correct the cited drug and manufacturing violations and provide adequate documentation; no response deadline is stated in the provided letter.

Who should pay attention

  • contract manufacturers that encapsulate or bottle supplements for this firm
  • retailers and distributors selling Pacific BioLogic products
  • consumers using supplements marketed for heart disease, headaches, pain, or immune conditions

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk
  2. Psyched Wellness Ltd.

    FDA warned Psyched Wellness that its Calm, Calmer and Santa Amanita muscaria supplements are adulterated new-dietary-ingredient products.

    High risk
  3. Wellmill, LLC dba Vitamix Laboratories

    FDA warned Vitamix Laboratories that its juice-with-probiotics products were adulterated because it lacked required hazard controls and a 5-log pathogen reduction.

    High risk
  4. American Pharma Mfg. Inc.

    FDA warns American Pharma Mfg. of serious dietary supplement manufacturing violations at its Ontario, CA facility.

    High risk